Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alendronate for prevention of postmenopausal bone loss
NCT00463268Phase 3Completed
- Sponsor
- CHU UCL Namur - site Godinne
- Start
- Sep 2007
- Primary completion
- Jan 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in osteopenia comparing Alendronate with Placebo (2 arms). Primary endpoint: Percentage of lumbar BMD modification at 2 years. Started Sep 2007; status: completed.
02
Drugs
alendronate
03
Conditions
osteopenia
Beyond the preview
Go deeper on NCT00463268.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00463268.